US regulatory status: approved. Molecular target: Synaptosomal-associated protein 25.
- Target
- Synaptosomal-associated protein 25
- Mechanism
- Synaptosomal-associated protein 25 inhibitor
pharma · Epilepsy · Attention-Deficit/Hyperactivity Disorder (ADHD) · SUPN
SUPERNUS PHARMACEUTICALS
SUPERNUS PHARMACEUTICALS, INC.
SUPERNUS PHARMACEUTICALS drug portfolio — 25 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
9715 Key West Ave, Rockville, Maryland 20850, US HQ
2005 Founded
828 Employees
Public company Type
SUPN · NYSE Ticker
Company details
- Status
- Public
- HQ
- 9715 Key West Ave, Rockville, Maryland 20850, US
- Founded
- 2005
- Employees
- 828
- Programs
- 55
- Drugs
- 25
- Patents
- 68
SUPERNUS PHARMACEUTICALS pipeline
Portfolio lens on 25 drugs and development assets — regulatory status, targets, and deep links to NovaPharmaNews drug profiles.
SUPERNUS PHARMACEUTICALS drug portfolio — 25 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
Drug portfolio
-
-
US regulatory status: approved. Molecular target: Fatty-acid amide hydrolase 1.
- Target
- Fatty-acid amide hydrolase 1
- Mechanism
- Cyclooxygenase inhibitor
-
Development asset linked to SUPERNUS PHARMACEUTICALS in public FDA and regional records.
-
US regulatory status: approved. Molecular target: Glutamate [NMDA] receptor.
- Target
- Glutamate [NMDA] receptor
- Mechanism
- Glutamate [NMDA] receptor antagonist
-
Development asset linked to SUPERNUS PHARMACEUTICALS in public FDA and regional records.
-
apomorphine
Genito-urinary system and sex hormones (G04)Genito-urinary system and sex hormones (G04) compound in SUPERNUS PHARMACEUTICALS's portfolio. Mechanism: D2-like dopamine receptor agonist.
- Mechanism
- D2-like dopamine receptor agonist
-
US regulatory status: approved. Molecular target: D2-like dopamine receptor.
- Target
- D2-like dopamine receptor
- Mechanism
- D2-like dopamine receptor agonist
-
botulinum toxin type b
Musculo-skeletal system (M03)US regulatory status: approved. Molecular target: Vesicle-associated membrane protein 2.
- Target
- Vesicle-associated membrane protein 2
- Mechanism
- Vesicle-associated membrane protein 2 inhibitor
-
US regulatory status: approved. Molecular target: GABA-A receptor; anion channel.
- Target
- GABA-A receptor; anion channel
- Mechanism
- GABA-A receptor; anion channel positive allosteric modulator
-
Development asset linked to SUPERNUS PHARMACEUTICALS in public FDA and regional records.
-
Development asset linked to SUPERNUS PHARMACEUTICALS in public FDA and regional records.
-
US regulatory status: approved.
-
Development asset linked to SUPERNUS PHARMACEUTICALS in public FDA and regional records.
-
Development asset linked to SUPERNUS PHARMACEUTICALS in public FDA and regional records.
-
Development asset linked to SUPERNUS PHARMACEUTICALS in public FDA and regional records.
-
Development asset linked to SUPERNUS PHARMACEUTICALS in public FDA and regional records.
-
US regulatory status: approved. Molecular target: D(2) dopamine receptor.
- Target
- D(2) dopamine receptor
- Mechanism
- Dopamine D2 receptor antagonist
-
Development asset linked to SUPERNUS PHARMACEUTICALS in public FDA and regional records. Mechanism: Mu opioid receptor agonist.
- Mechanism
- Mu opioid receptor agonist
-
US regulatory status: approved. Molecular target: Sodium channel alpha subunit.
- Target
- Sodium channel alpha subunit
- Mechanism
- Sodium channel alpha subunit blocker
-
Development asset linked to SUPERNUS PHARMACEUTICALS in public FDA and regional records.
-
Development asset linked to SUPERNUS PHARMACEUTICALS in public FDA and regional records.
-
Development asset linked to SUPERNUS PHARMACEUTICALS in public FDA and regional records.
-
US regulatory status: approved. Molecular target: Carbonic anhydrase 2.
- Target
- Carbonic anhydrase 2
- Mechanism
- GABA-A receptor; anion channel positive modulator
-
Development asset linked to SUPERNUS PHARMACEUTICALS in public FDA and regional records.
-
US regulatory status: approved. Molecular target: Sodium-dependent noradrenaline transporter.
- Target
- Sodium-dependent noradrenaline transporter
- Mechanism
- Norepinephrine transporter inhibitor